Learn About Myelodysplastic Syndrome (MDS)

What is the definition of Myelodysplastic Syndrome (MDS)?

Myelodysplastic syndrome is a group of disorders in which the blood cells produced in the bone marrow do not mature into healthy cells. This leaves you with fewer healthy blood cells in your body. The blood cells that have matured may not function properly.

Myelodysplastic syndrome (MDS) is a form of cancer. In about a third of people, MDS may develop into acute myeloid leukemia (AML).

What are the alternative names for Myelodysplastic Syndrome (MDS)?

Myeloid malignancy; Myelodysplastic syndrome; MDS; Preleukemia; Smoldering leukemia; Refractory anemia; Refractory cytopenia

What are the causes of Myelodysplastic Syndrome (MDS)?

Stem cells in bone marrow form different types of blood cells. With MDS, the DNA in stem cells becomes damaged. Because the DNA is damaged, the stem cells cannot produce healthy blood cells.

The exact cause of MDS is not known. For most cases, there is no known cause.

Risk factors for MDS include:

  • Certain genetic disorders
  • Exposure to environmental or industrial chemicals, fertilizers, pesticides, solvents, or heavy metals
  • Smoking

Prior cancer treatment increases the risk for MDS. This is called secondary or treatment-related MDS.

  • Certain chemotherapy medicines increase the chance of developing MDS. This is a major risk factor.
  • Radiation therapy, when used with chemotherapy, increases the risk for MDS even more.
  • People who have stem cell transplants may develop MDS because they also receive high doses of chemotherapy.

MDS usually occurs in adults age 60 years and older. It is more common in men.

What are the symptoms of Myelodysplastic Syndrome (MDS)?

Early stage MDS often has no symptoms. MDS is often discovered during other blood tests.

People with very low blood counts often experience symptoms. Symptoms depend on the type of blood cell affected, and they include:

  • Weakness or tiredness due to anemia
  • Shortness of breath
  • Easy bruising and bleeding
  • Small red or purple pinpoint dots under the skin caused by bleeding
  • Frequent infections and fever
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Myelodysplastic Syndrome (MDS)?

Your treatment will depend on several factors:

  • Whether you are low-risk or high-risk
  • The type of MDS you have
  • Your age, health, and other conditions you may have, such as diabetes or heart disease

The goal of MDS treatment is to prevent leukemia from developing and to prevent problems due to a shortage of blood cells, infections and bleeding. It may consist of:

  • Blood transfusion
  • Medicines that promote the production of blood cells
  • Medicines that suppress the immune system
  • Low-dose chemotherapy to improve blood cell counts
  • Stem cell transplantation

Your provider may try one or more treatments to see what your MDS responds to.

Who are the top Myelodysplastic Syndrome (MDS) Local Doctors?
Marcos J. De Lima
Elite in Myelodysplastic Syndrome (MDS)
Hematology Oncology | Oncology | Hematology
Elite in Myelodysplastic Syndrome (MDS)
Hematology Oncology | Oncology | Hematology

Osu Internal Medicine LLC

410 W 10th Ave, 
Columbus, OH 
Languages Spoken:
English
Accepting New Patients

Marcos De Lima is a Hematologist Oncology specialist and an Oncologist in Columbus, Ohio. Dr. De Lima and is rated as an Elite provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Graft. Dr. De Lima is currently accepting new patients.

Elite in Myelodysplastic Syndrome (MDS)
Hematology | Oncology | Hematology Oncology
Elite in Myelodysplastic Syndrome (MDS)
Hematology | Oncology | Hematology Oncology

MD Anderson

2130 W Holcombe Blvd, Life Sciences Plaza, 
Houston, TX 
Languages Spoken:
English
Offers Telehealth

Tapan Kadia is a Hematologist and an Oncologist in Houston, Texas. Dr. Kadia and is rated as an Elite provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Myelodysplastic Syndrome (MDS)
Elite in Myelodysplastic Syndrome (MDS)
1275 York Ave, 
New York, NY 
Languages Spoken:
English

Virginia Klimek is an Oncologist in New York, New York. Dr. Klimek and is rated as an Elite provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). Her top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Chronic Myelomonocytic Leukemia (CMML), and Bone Marrow Aspiration.

What is the outlook (prognosis) for Myelodysplastic Syndrome (MDS)?

The outlook will depend on your type of MDS and severity of symptoms. Your overall health also may affect your chances of recovery. Many people have stable MDS that does not progress into cancer for years, if ever.

Some people with MDS may develop AML.

What are the possible complications of Myelodysplastic Syndrome (MDS)?

MDS complications include:

  • Bleeding
  • Infections such as pneumonia, gastrointestinal infections, urinary infections
  • AML
When should I contact a medical professional for Myelodysplastic Syndrome (MDS)?

Contact your provider if you:

  • Feel weak and tired most of the time
  • Bruise or bleed easily, have bleeding of the gums or frequent nosebleeds
  • You notice red or purple spots of bleeding under the skin
What are the latest Myelodysplastic Syndrome (MDS) Clinical Trials?
A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Treatment Trial

Summary: This phase II MyeloMATCH treatment trial compares the usual treatment of cedazuridine-decitabine (ASTX727) to the combination treatment of ASTX727 and enasidenib in treating patients with higher-risk, IDH2-mutated myelodysplastic syndrome (MDS). ASTX727 is a combination of two drugs, decitabine and cedazuridine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It pre...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1 Study of AUTX-703 in Participants With Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

Summary: This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.

Who are the sources who wrote this article ?

Published Date: December 31, 2023
Published By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

What are the references for this article ?

National Cancer Institute website. Myelodysplastic/myeloproliferative neoplasms treatment (PDQ) - health professional version. www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq. Updated January 26, 2022. Accessed March 19, 2024.

Nguyen PL, Hasserjian RP. Myelodysplastic syndromes. In: Hsi ED, ed. Hematopathology: Foundations of Diagnostic Pathology. 3rd ed. Philadelphia PA: Elsevier; 2018:chap 18.

Stone RM. Myelodysplastic syndromes. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 167.